slide1 l.
Skip this Video
Loading SlideShow in 5 Seconds..
Antifungals Market to 2016 PowerPoint Presentation
Download Presentation
Antifungals Market to 2016

Loading in 2 Seconds...

play fullscreen
1 / 6

Antifungals Market to 2016 - PowerPoint PPT Presentation

  • Uploaded on

The Antifungals Market is Forecast To Grow At Moderate Rate From 2009 to 2016

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

Antifungals Market to 2016

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin


The Antifungals Market is Forecast To Grow At Moderate Rate From 2009 to 2016

GBI research forecasts the global antifungals market to grow at a rate of 1.9% annually for the next seven years to reach $8.4 billion by 2016. It was valued at $7.4 billion in 2009. This moderate growth will primarily be supported by an increase in the treatment seeking and the diagnosed rates during the forecast period. The growth of the antifungals market during the forecast period will not be much lower than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons: firstly, the antifungals market is dominated by generic products which generate less revenue per unit sold; secondly, the pipeline for the antifungals market is weak with a small number of molecules across different stages of development. However, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.

For further details, please click or add the below link to your browser:


Antifungals Market Will Be Driven By Growth in Treatment Seeking Rate and High Diagnosed Rate In Future

The Introduction of Posconazole (Noxafil) for the treatment of invasive aspergillosis has been significant in reducing the mortality rates of the infected patients. Noxafil is considered to be more effective with fewer side effects, and its cost of treatment is lower than the earlier treatments. Based on these factors, the percentage of the population being treated for invasive aspergillosis is increasing.

Dermatophytosis is a fungal infection that causes rashes and visible marks and itching on the skin. Fungal infections are common in the obese and diabetic populations. As the total diabetic population is increasing, GBI Research expects more infected patients will seek treatment.

A high diagnosis rate acts as a driver for the market growth. The current diagnostic techniques involve self diagnosis, fungal culture, microscopy and Enzyme-linked Immunosorbent Assay (ELISA) tests. The sensitivity and accuracy of diagnostic methods such as ELISA and microscopy are high. This increases the possibility of diagnosis and decreases the incidence of misdiagnosis. Advances in the diagnostic techniques and awareness among patients will also increase the number of patients getting diagnosed with the disease and this will further support market growth


A Weak Pipeline with Few Molecules across Various Developmental Stages

The current pipeline contains only 31 projects across the three indications. Candidiasis accounts for 39%. A total of 12 R&D programs are being carried out for candidiasis, which makes this the most active in terms of its research activities among all of the antifungals market projects in the pipeline. In the candidiasis therapeutics pipeline, the Phase IIl development stage accounts for 33%, followed by the Phase ll stage of development, which accounts for 25% and the Pre-clinical development stage, that accounts for 25%. The Phase l stage has the least number of molecules, accounting for 17% of the total candidiasis pipeline. A total of nine R&D programs are being carried out for dermatophytosis, the Phase II development stage accounts for 67%, all the molecules in the other stages such as Preclinical, Phase l, and Phase lll account for 11% each. In the aspergillosis therapeutics pipeline, the Phase II and Preclinical development stages account for 30% each followed by the Phase lll and Phase l stage molecules that account for 20% each.

GBI Research, a leading business intelligence provider, has released its latest research Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin”, which provides insights on antifungals sales and price forecasts until 2016. The report also examines global treatment usage patterns of antifungal therapies. The geographical distribution of


antifungal therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report includes insights into the antifungal Research and Development (R&D) pipeline and potential future blockbusters up to 2016. The report provides an in-depth analysis of the top three antifungal therapeutic indications, which are aspergillosis, dermatophytosis and candidiasis. It also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report explores the competitive landscape including top companies benchmarking and the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving antifungals therapies are also presented.

It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:


Visit our report store:

For more details contact:

North America: +1 646 395 5477

Europe: +44 207 753 4299

+44 1204 543 533

Asia Pacific: +91 40 6616 6782